217 related articles for article (PubMed ID: 12172215)
21. Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.
Qian J; Xu T; Pan P; Sun W; Hu G; Cai J
Pharmacogenomics J; 2024 Apr; 24(3):13. PubMed ID: 38637522
[TBL] [Abstract][Full Text] [Related]
22. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
24. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
Wang Y; Zhou L; Dutreix C; Leroy E; Yin Q; Sethuraman V; Riviere GJ; Yin OQ; Schran H; Shen ZX
Br J Clin Pharmacol; 2008 Jun; 65(6):885-92. PubMed ID: 18384443
[TBL] [Abstract][Full Text] [Related]
25. [Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].
Fux R; Meisner C; Schwab M; Lorenz G; Mörike K; Gleiter CH
Z Arztl Fortbild Qualitatssich; 2004 Nov; 98(8):689-94. PubMed ID: 15646732
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Mar; 64(3):275-82. PubMed ID: 18043911
[TBL] [Abstract][Full Text] [Related]
27. [Effects of CYP2D6
Zhu Q; Lai W; Li L; Li H; Zhong S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):328-336. PubMed ID: 31068311
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.
Taguchi M; Nozawa T; Kameyama T; Inoue H; Takesono C; Mizukami A; Hashimoto Y
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):385-8. PubMed ID: 12915955
[TBL] [Abstract][Full Text] [Related]
29. Metoprolol oxidation polymorphism in Brazilian elderly cardiac patients.
Neves DV; Lanchote VL; de Souza L; Hayashida M; Nogueira MS; de Moraes NV; Cesarino EJ
J Pharm Pharmacol; 2013 Sep; 65(9):1347-53. PubMed ID: 23927473
[TBL] [Abstract][Full Text] [Related]
30. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
[TBL] [Abstract][Full Text] [Related]
31. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
[TBL] [Abstract][Full Text] [Related]
32. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
Sharp CF; Gardiner SJ; Jensen BP; Roberts RL; Troughton RW; Lainchbury JG; Begg EJ
Pharmacogenomics J; 2009 Jun; 9(3):175-84. PubMed ID: 19365402
[TBL] [Abstract][Full Text] [Related]
34. The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.
Poulussen FCP; Peters BJ; Hua KH; Houthuizen P; Grouls RJ; Deenen MJ
Pharmacogenet Genomics; 2019 Sep; 29(7):179-182. PubMed ID: 31107373
[TBL] [Abstract][Full Text] [Related]
35. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
36. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
Wennerholm A; Dandara C; Sayi J; Svensson JO; Abdi YA; Ingelman-Sundberg M; Bertilsson L; Hasler J; Gustafsson LL
Clin Pharmacol Ther; 2002 Jan; 71(1):77-88. PubMed ID: 11823760
[TBL] [Abstract][Full Text] [Related]
37. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
[TBL] [Abstract][Full Text] [Related]
38. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
Lee CM; Kang P; Cho CK; Park HJ; Lee YJ; Bae JW; Choi CI; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Jun; 45(6):433-445. PubMed ID: 35763157
[TBL] [Abstract][Full Text] [Related]
39. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
[TBL] [Abstract][Full Text] [Related]
40. Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients.
Taguchi M; Nozawa T; Mizumaki K; Inoue H; Tahara K; Takesono C; Hashimoto Y
Biol Pharm Bull; 2004 Oct; 27(10):1642-8. PubMed ID: 15467211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
